Drug Patents owned by Sunovion Pharms Inc

1. Drug name - APTIOM

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9206135 SUNOVION PHARMS INC Asymmetric catalytic reduction of oxcarbazepine
Apr, 2026

(3 years from now)

CN101277937A SUNOVION PHARMS INC Asymmetric Catalytic Reduction Of Oxcarbazepine
Apr, 2026

(3 years from now)

CN101277937B SUNOVION PHARMS INC Asymmetric Catalytic Reduction Of Oxcarbazepine
Apr, 2026

(3 years from now)

IN200801071P1 SUNOVION PHARMS INC Asymmetric Catalytic Reduction Of Oxcarbazepine
Apr, 2026

(3 years from now)

IN263294B SUNOVION PHARMS INC A Process For Preparing (S) Or (R) -10,11-Dihydro-10-Hydroxy-5H-Dibenz[B,F] Azepine-5-Carboxamide
Apr, 2026

(3 years from now)

EP2319836B1 SUNOVION PHARMS INC Asymmetric Catalytic Reduction Of Oxcarbazepine
Apr, 2026

(3 years from now)

EP2319836A1 SUNOVION PHARMS INC Asymmetric Catalytic Reduction Of Oxcarbazepine
Apr, 2026

(3 years from now)

EP1915346A1 SUNOVION PHARMS INC Asymmetric Catalytic Reduction Of Oxcarbazepine
Apr, 2026

(3 years from now)

EP1915346B1 SUNOVION PHARMS INC Asymmetric Catalytic Reduction Of Oxcarbazepine
Apr, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10675287 SUNOVION PHARMS INC Methods of treatment of partial onset seizures using eslicarbazepine acetate May, 2025

(2 years from now)

US10702536 SUNOVION PHARMS INC Methods of treatment of partial onset seizures using eslicarbazepine acetate May, 2025

(2 years from now)

US10695354 SUNOVION PHARMS INC Methods of treatment of partial onset seizures using eslicarbazepine acetate May, 2025

(2 years from now)

US9643929 SUNOVION PHARMS INC Asymmetric catalytic reduction of oxcarbazepine Apr, 2026

(3 years from now)

US9763954 SUNOVION PHARMS INC Therapeutical uses of eslicarbazepine Sep, 2028

(5 years from now)

US9566244 SUNOVION PHARMS INC Pharmaceutical composition comprising licarbazepine acetate Oct, 2028

(6 years from now)

US10912781 SUNOVION PHARMS INC Pharmaceutical composition comprising licarbazepine acetate Oct, 2028

(6 years from now)

US8372431 SUNOVION PHARMS INC Pharmaceutical composition comprising licarbazepine acetate Apr, 2030

(7 years from now)

US9750747 SUNOVION PHARMS INC Treatments involving eslicarbazepine acetate or eslicarbazepine Aug, 2032

(9 years from now)

Drugs and Companies using ESLICARBAZEPINE ACETATE ingredient

Treatment: Treatment of partial-onset seizures in a patient with refractory partial-onset seizures; treatment of partial-onset seizures; Treatment of partial-onset seizures; Treatment of partial-onset seizures in patients with epilepsy who have been previously treated with oxcarbazepine; Treatment of partial-onset seizures in a patient suffering from or susceptible to absence seizures; treatment of partial-onset seizures

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
200MG TABLET;ORAL Prescription
400MG TABLET;ORAL Prescription
600MG TABLET;ORAL Prescription
800MG TABLET;ORAL Prescription

2. Drug name - KYNMOBI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8663687 SUNOVION PHARMS INC Film compositions for delivery of actives Feb, 2023

(3 months from now)

US8765167 SUNOVION PHARMS INC Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions Feb, 2024

(1 year, 4 months from now)

US8603514 SUNOVION PHARMS INC Uniform films for rapid dissolve dosage form incorporating taste-masking compositions Apr, 2024

(1 year, 5 months from now)

US10821074 SUNOVION PHARMS INC Sublingual and buccal film compositions Aug, 2029

(6 years from now)

US9044475 SUNOVION PHARMS INC Sublingual apomorphine Jun, 2030

(7 years from now)

US9326981 SUNOVION PHARMS INC Sublingual apomorphine Jun, 2030

(7 years from now)

US10420763 SUNOVION PHARMS INC Sublingual apomorphine Jun, 2030

(7 years from now)

US9283219 SUNOVION PHARMS INC Sublingual films Jun, 2030

(7 years from now)

US9669019 SUNOVION PHARMS INC Sublingual apomorphine Jun, 2030

(7 years from now)

US9669021 SUNOVION PHARMS INC Sublingual apomorphine Jun, 2030

(7 years from now)

US8414922 SUNOVION PHARMS INC Sublingual films Dec, 2031

(9 years from now)

US8846074 SUNOVION PHARMS INC Sublingual films Dec, 2031

(9 years from now)

US10959943 SUNOVION PHARMS INC Methods of treating Parkinson's disease by administration of apomorphine to an oral mucosa Apr, 2036

(13 years from now)

US10449146 SUNOVION PHARMS INC Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa Apr, 2036

(13 years from now)

Drugs and Companies using APOMORPHINE HYDROCHLORIDE ingredient

Treatment: Treatment of 'off' episodes in patients with parkinson's disease

Dosage: FILM;SUBLINGUAL

More Information on Dosage
Strength Dosage Availability
10MG FILM;SUBLINGUAL Prescription
15MG FILM;SUBLINGUAL Prescription
20MG FILM;SUBLINGUAL Prescription
25MG FILM;SUBLINGUAL Prescription
30MG FILM;SUBLINGUAL Prescription

3. Drug name - LATUDA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE45573 SUNOVION PHARMS INC Process for producing imide compound
Jun, 2025

(2 years from now)

CN100422178C SUNOVION PHARMS INC Method For Producing Imide Compound
Jul, 2024

(1 year, 9 months from now)

CN1832946A SUNOVION PHARMS INC Method For Producing Imide Compound
Jul, 2024

(1 year, 9 months from now)

IN200600349P4 SUNOVION PHARMS INC Process For Producing Imide Compound
Jul, 2024

(1 year, 9 months from now)

IN235208B SUNOVION PHARMS INC Process For Producing Imide Compound
Jul, 2024

(1 year, 9 months from now)

EP1652848A1 SUNOVION PHARMS INC Process For Producing Imide Compound
Jul, 2024

(1 year, 9 months from now)

EP1652848A4 SUNOVION PHARMS INC Process For Producing Imide Compound
Jul, 2024

(1 year, 9 months from now)

EP1652848B1 SUNOVION PHARMS INC Process For Producing Imide Compound
Jul, 2024

(1 year, 9 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9174975 SUNOVION PHARMS INC Remedy for integration dysfunction syndrome Feb, 2024

(1 year, 4 months from now)

US9815827 SUNOVION PHARMS INC Agent for treatment of schizophrenia Feb, 2024

(1 year, 4 months from now)

US9174975

(Pediatric)

SUNOVION PHARMS INC Remedy for integration dysfunction syndrome Aug, 2024

(1 year, 10 months from now)

USRE45573

(Pediatric)

SUNOVION PHARMS INC Process for producing imide compound Dec, 2025

(3 years from now)

US8883794 SUNOVION PHARMS INC Pharmaceutical composition May, 2026

(3 years from now)

US9555027 SUNOVION PHARMS INC Pharmaceutical composition May, 2026

(3 years from now)

US9907794 SUNOVION PHARMS INC Pharmaceutical composition May, 2026

(3 years from now)

US8729085 SUNOVION PHARMS INC Pharmaceutical composition May, 2026

(3 years from now)

US8883794

(Pediatric)

SUNOVION PHARMS INC Pharmaceutical composition Nov, 2026

(4 years from now)

US8729085

(Pediatric)

SUNOVION PHARMS INC Pharmaceutical composition Nov, 2026

(4 years from now)

US9827242 SUNOVION PHARMS INC Method of treatment for mental disorders May, 2031

(8 years from now)

US9259423 SUNOVION PHARMS INC Method of treatment for mental disorders May, 2031

(8 years from now)

US9259423

(Pediatric)

SUNOVION PHARMS INC Method of treatment for mental disorders Nov, 2031

(9 years from now)

Drugs and Companies using LURASIDONE HYDROCHLORIDE ingredient

Treatment: Treatment of schizophrenia with improvement in negative symptoms and/or cognitive dysfunction of schizophrenia; Treatment of major depressive episodes associated with bipolar i disorder; treatment of schizophrenia; Treatment of schizophrenia; Treatment of schizophrenia with improvement in attention function in schizophrenia; treatment of bipolar depression with improvement in attention function in bipolar disorder; Treatment of schizophrenia or bipolar depression with improvement in attention function in schizophrenia and/or bipolar disorder

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
20MG TABLET;ORAL Prescription
40MG TABLET;ORAL Prescription
60MG TABLET;ORAL Prescription
80MG TABLET;ORAL Prescription
120MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.